The Ideal Pharma Country Manager: South Korea (DHR International)
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
The Korea Pharmaceutical Manufacturers Association, since its foundation in 1945, along with pharmaceutical companies, has been committed to improve healthcare for all mankind and develop pharmaceutical industry.
With about 190 member companies, KPMA expanded R&D investments since the implementation of Drug Substance Patent Law in 1987 to place Korea in the world’s 10th country to commercialize new molecular entities in 2003. Up until the end of 2008, 14 new molecular entities products were developed in the country, with 45 projects from 29 companies undergoing clinical studies, 61 potential candidates currently under new drugs development phases and 40 cases of licensing out in 14 countries.
In order to manufacture safe medicines of the highest quality, 65 companies collectively invested 2 trillion won to upgrade manufacturing plants in compliance with c-GMP standards. In addition, to increase credibility in the international pharmaceutical market, Fair Competition Committee was established and Hotline Reporting Center for code compliance complaints was activated to escalate efforts in making all transaction as fair as possible. Market size of Korean pharmaceutical industry, gauged by values of drugs manufactured, in 2000 was 7.89 trillion won and the size grew substantially to 13.43 trillion won in 2007, almost doubling the size. Such a significant increase is attributed to rapid aging of the population, external and political factors that favorably affected the industry as well as continuous investments in R&D and GMP upgrades.
KPMA aims to strengthen collaboration of Korean companies with pharmaceutical companies already having experience in product launches in the overseas markets.
Contact details
161 Hyoryeong-ro, Seocho-gu, Seoul 137-849 Korea
TEL: +82 2 581 2101 / 2102
FAX: +82 2 581 2106
http://www.kpma.or.kr
kpma@kpma.or.kr
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides…
SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview,…
Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains…
Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools,…
The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation activities in the Korean life sciences sector. In this interview, Samuel Muk explains how he integrated…
Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at the Ajou University School of Medicine in South Korea is taking stock of his…
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The…
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are…
Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry…
It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building…
Examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Here, Eugene Kim, Seoul office leader of executive…
See our Cookie Privacy Policy Here
